Marie Curie Initial Training Network


1. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther. (2007) 81(1):104-107.
2. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. (2006) 23(2):312-328.
3. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol. Blood Marrow Transplant. (2006) 12(2):126-137.
4. Lagakos SW. Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties. Clin. Infect. Dis. (1993) 16 Suppl 1:S22-5.
5. Imielinski M, Baldassano RN, Griffiths A,et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat.Genet . (2009) 41(12):1335-1340.
6. Pociot F, Akolkar B, Concannon P, et al. Genetics of type 1 diabetes: what's next? Diabetes 59(7):1561-71.
7. Hansen JA, Chien JW, Warren EH, Zhao LP, Martin PJ. Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr. Opin. Hematol. 17(6):483-92.
8. Ogawa S, Matsubara A, Onizuka M, et al. Exploration of the genetic basis of GVHD by genetic association studies. Biol. Blood Marrow Transplant. (2009) 15(1 Suppl):39-41.
9. Dickinson AM, Pearce KF, Norden J, et al. Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia. Haematologica (2010) 95(6):922-7.
10. Pearce KF, Norden J, Ahmed S, et al. Genomic Risk Factors and Biomarkers as predictors of GVHD after hematopoietic stem cell transplantation. (EBMT abstract 2012).
11. The UK IBD Genetics Consortium & the Wellcome Trust Case Control Consortium 2. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region Nat.Genet. (2009) 41(12):1330-1334.
12. Dickinson AM, Holler E. Polymorphisms of cytokine and innate immunity genes and GvHD. Best practice & research. Clinical haematology (2008) 21(2):149-64.
13. Benichou J, Ben-Hamo R, Louzoun Y, Efroni S. Rep-Seq: Uncovering the immunological repertoire through next generation sequencing. Immunology (Accepted for publication).
14. Gratwohl A, Hermans J, Goldman JM,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet (1998) 352(9134):1087-1092.
15. Ludajic K, Balavarca Y, Bickeboller H, et al. Impact of HLA-DPB1 allelic and single amino acid mismatches on HSCT. B. J. Haematol. (2008) 142(3):436-443.
16. Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin. Cancer. Biol. (2008) 18(2):131-140.
17. Calin GA, Croce CM. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin. Oncol. (2006) 33(2):167-173.
18. Lawrie CH. MicroRNA expression in lymphoma. Expert Opin. Biol. Ther. (2007) 7(9):1363-1374.
19. Strietholt S, Maurer B, Peters MA, Pap T, Gay S. Epigenetic modifications in rheumatoid arthritis. Arthritis Res. Ther. (2008) 10(5):219.
20. Sonkoly E, Wei T, Janson PC, et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One (2007) 2(7):e610.
21. Baron C, Somogyi R, Greller LD, et al. Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med (2007) 4(1):e23.
22. Novota P, Sviland L, Zinocker S, et al. Correlation of Hsp70-1 and Hsp70-2 gene expression with the degree of graft-versus-host reaction in a rat skin explant model. Transplantation (2008) 85(12):1809-1816.
23. Novota P, Zinocker S, Norden J, et al. Expression profiling of major histocompatibility and natural killer complex genes reveals candidates for controlling risk of graft versus host disease. PLoS One 6(1):e16582.
24. Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood (2005) 106(9):3308-3313.
25. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. (2009) 10(9):855-864.
26. Allan SE, Broady R, Gregori S, et al. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol. Rev. (2008) 223:391-421.
27. Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood (2005) 106(8):2903-2911.
28. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10(12):849-859.
29. Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 120(5):1479-1493.
30. Shenghui Z, Yixiang H, Jianbo W, et al. Elevated frequencies of CD4 CD25 CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int. J. Cancer 129(6):1373-1381.
31. Landfried K, Bataille F, Rogler G, et al. Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. Clin. Exp. Immunol. 159(1):87-92.
32. Landfried K, Zhu W, Waldhier MC, et al. Tryptophan catabolism is associated with acute GvHD following human allogeneic stem cell transplantation and indicates activation of indole-amine-2,3-dioxygenase. Blood e-pub 2011/11/01.
33. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J. Exp. Med. (2004) 199(8):1133-1142.
34. Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin.Cancer Res. (2007) 13(20):6107-6114.
35. Greinix HT, Pohlreich D, Kouba M, et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol. Blood Marrow Transplant. (2008) 14(2):208-219.
36. Kuzmina Z, Weigl R, Krenn K, et al. Excess of BAFF and distortion of B-cell homeostasis in patients with newly diagnosed bronchiolitis obliterans syndrome associated with chronic graft-versus-host disease. Bone Marrow Transplant. (2011) 46(suppl 1):O152.
37. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood (2000) 96(7):2426-2431.
38. Gasparro FP, Felli A, Schmitt IM. Psoralen photobiology: the relationship between DNA damage, chromatin structure, transcription, and immunogenic effects. Recent Results Cancer Res. (1997) 143:101-127.
39. Greinix HT, van Besien K, Elmaagacli AH, et al. Progressive Improvement in Cutaneous and Extracutaneous Chronic Graft-versus-Host Disease after a 24-Week Course of Extracorporeal Photopheresis-Results of a Crossover Randomized Study. Biol. Blood Marrow Transplant. 17(12):1775-1782.
40. Zinocker S, Sviland L, Dressel R, Rolstad B. Kinetics of lymphocyte reconstitution after allogeneic bone marrow transplantation: markers of graft-versus-host disease. J.Leukoc. Biol. (2011) 90(1):177-187.
41. Naper C, Kveberg L, Engh E, et al. Partial NK cell tolerance induced by radioresistant host cells in rats transplanted with MHC-mismatched bone marrow. Int. Immunol. 22(12):973-980.
42. Nestvold JM, Omdal BK, Dai KZ, et al. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease. Transplantation (2008) 85(1):102-111.7
43. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 295(5562):2097-100.
44. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 363(9419):1439-1441.
45. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 371(9624):1579-1586.
46. Sviland L, Dickinson AM. A human skin explant model for predicting graft versus host disease following bone marrow transplantation. J. Clin. Pathol. (1999) 52(12):910-913.
47. Mellor AL, Munn DH. Tryptophan catabolism and regulation of adaptive immunity. J. Immunol. (2003) 170(12):5809-5813.
48. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood (2007) 109(1):228-234.
49. Nasef A, Mathieu N, Chapel A, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation (2007) 84(2):231-237.
50. Jones E, English A, Churchman SM, et al. Large-scale extraction and characterization of CD271+ multipotential stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on uncultured or minimally cultured multipotential stromal cells. Arthritis Rheum. 62(7):1944-1954.
51. Sviland L, Dickinson AM, Carey PJ,et al. An in vitro predictive test for clinical graft versus host disease, correlation with clinical GvHD stage in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. (1990) 5:105-109.
52. Morecki S, Lindhofer H, Yacovlev E,et al. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood (2006) 107(4):1564-1569.
53. Sviland L, Hromadníková I, Sedlácek P, et al. Histological correlation between different centers using the skin explant model to predict graft-versus-host disease following bone marrow transplantation. Hum. Immunol. (2001) 62(11):1277-1281.
54. Proske D, Blank M, Buhmann R, Resch A. Aptamers--basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. (2005) 69(4):367-374.
55. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New England Journal of Medicine (1995) 333(16):1038-1044.
56. Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood (2004) 103(9):3565-3572.